Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

Applied Cells Inc. and Immuneel Therapeutics Private Limited today announced that the companies have entered into a collaboration framework to jointly evaluate application of Applied Cells' MARS(R) ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

Diffuse intrinsic pontine glioma (DIPG) is one of the most devastating pediatric brain tumors. It sits in the brainstem where it cannot be surgically removed, responds poorly to chemotherapy, and ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating peptide iRGD. Preclinical studies showed the cells had synergistic antitumor ...